source
- Bristol Myers reports Phase 3 data showing mezigdomide extends survival in relapsed multiple myelomaBristol Myers Squibb presented Phase 3 results for its experimental multiple myeloma drug mezigdomide at the American Society of Clinical Oncology meeting. The study evaluated mezigdomide combined…
- Bristol Myers reports 52% reduction in progression risk for next-gen multiple myeloma drug in Phase 3 trialBristol Myers Squibb said its next-generation multiple myeloma therapy, positioned as a successor to Pomalyst, lowered the risk of disease progression or death by 52% when added to a standard combi…